Insulet vs West Pharmaceutical Services
PODD and WST side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PODD and WST compare
West Pharmaceutical Services is the larger company, worth 2.8 times as much as Insulet ($29.0B against $10.4B).
On earnings, Insulet is cheaper: it trades at 28.0× trailing earnings, against 46.3× for West Pharmaceutical Services.
Insulet grew revenue faster over the last twelve months (29.4% versus 12.6% for West Pharmaceutical Services).
West Pharmaceutical Services keeps more of each dollar of sales as profit, with a net margin of 18.8% compared with 12.3% at Insulet.
West Pharmaceutical Services pays a dividend yielding 0.21%; Insulet does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PODD | WST |
|---|---|---|
| Size and price | ||
| Market cap | $10.4B | $29.0B |
| Share price | $149.68 | $412.62 |
| Change, 1 year | −52.7% | 44.9% |
| Change, 5 years | −51.4% | 2.2% |
| Beta (5Y) | 0.88 | 1.05 |
| Employees | 5,400 | 11K |
| StockData Score | ||
| Total score | 20 | 20 |
| Valuation score | 4 (better) | 1 |
| Growth score | 5 (better) | 4 |
| Performance score | 6 (better) | 5 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 28.0× (better) | 46.3× |
| P/S | 3.4× (better) | 8.5× |
| P/B | 7.3× (better) | 9.8× |
| EV/EBITDA | 17.5× (better) | 29.8× |
| P/FCF | 35.3× (better) | 64.0× |
| PEG | 0.10 | – |
| FCF yield | 2.8% (better) | 1.6% |
| Fair value | $243.94 | $314.51 |
| Margin of safety | 38.6% (better) | −31.2% |
| Growth | ||
| Revenue growth (TTM) | 29.4% (better) | 12.6% |
| Revenue growth, 5Y average | 24.5% (better) | 7.4% |
| Net income growth (TTM) | 59.0% (better) | 29.9% |
| EPS growth (TTM) | 64.1% (better) | 32.2% |
| EPS growth, 5Y average | 103% (better) | 8.2% |
| Profitability | ||
| Gross margin | 71.1% (better) | 37.6% |
| Operating margin | 16.9% | 23.0% (better) |
| Net margin | 12.3% | 18.8% (better) |
| FCF margin | 9.6% | 13.3% (better) |
| Return on equity | 26.0% (better) | 21.2% |
| Return on invested capital | 21.9% | 23.0% (better) |
| Financial health | ||
| Debt / equity | 0.67 | 0.07 (better) |
| Net debt / EBITDA | 0.67 (better) | −0.27 |
| Interest coverage | 8.8× | 96.3× (better) |
| Current ratio | 2.48 | 2.82 (better) |
| Altman Z-score | 5.70 | 19.43 (better) |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.21% |
| Payout ratio | – | 9.8% |
| Years of dividend growth | – | 16 |
| Dividend growth, 5Y average | – | 5.4% |
| Buyback yield | 3.2% (better) | 2.4% |
| Shareholder yield | 3.2% (better) | 2.6% |
| Ownership | ||
| Held by institutions | 103% | 100% |
| Held by insiders | 0.48% | 0.66% |
| Insider net buying, 12 months | $2.3M (better) | −$6.6M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.8% | 3.0% |
Go deeper
- PODD stock overview
- PODD income statement
- PODD valuation and score
- WST stock overview
- WST income statement
- WST valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.